{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG001","lowerLimit":"15.8","upperLimit":"100.0","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Disease response and progression were determined using International Myeloma Working Group Uniform Response Criteria (IMWG-URC) 2016, assessed by the Investigator. Per IMWG, determination of disease response requires: serum free light chain (SFLC), serum and urine protein electrophoresis (SPEP, UPEP, respectively), serum and urine immunofixation (SIFE, UIFE, respectively), bone marrow aspirate (for CR confirmation), corrected calcium, and plasmacytoma evaluation, if present at screening.\n\nBest overall response is defined as a participant's best response during the study. Overall response rate is defined as the percentage of participants achieving a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with 1 prior line of therapy for multiple myeloma.","id":"OG000","title":"1 Prior Line of Therapy"},{"description":"Participants with ≥ 2 prior lines of therapy for multiple myeloma.","id":"OG001","title":"2+ Prior Lines of Therapy"}],"paramType":"NUMBER","populationDescription":"All enrolled and treated participants","reportingStatus":"POSTED","timeFrame":"Disease assessments were performed every 28 days up to 12 months from enrollment.","title":"Overall Response Rate (ORR) by Prior Lines of Therapy","type":"SECONDARY","unitOfMeasure":"percentage of participants"}